{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=B+complex&page=14", "query": { "intervention": "B complex", "page": 14 }, "page_size": 10 }, "pagination": { "page": 14, "page_size": 10, "total_count": 911, "total_pages": 92, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=B+complex&page=15&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=B+complex&page=13&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-19T08:43:57.561Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04098393", "title": "Giving Chemotherapy for a Shortened Amount of Time Before a Stem Cell Transplantation", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hematologic Malignancies" ], "interventions": [ { "name": "Busulfan 3.2 mg/kg/day", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Antithymocyte globulin (ATG)", "type": "DRUG" }, { "name": "Busulfan 0.8 mg/kg", "type": "DRUG" }, { "name": "Allogeneic hematopoietic cell transplantation (Allo-HCT)", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 39, "start_date": "2019-09-18", "completion_date": "2026-09", "has_results": false, "last_update_posted_date": "2026-06-30", "last_synced_at": "2026-10-19T08:43:57.561Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04098393" }, { "nct_id": "NCT00278148", "title": "Erlotinib, Paclitaxel, and Carboplatin Combined With Radiation Therapy for Stage III Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "carboplatin", "type": "DRUG" }, { "name": "Erlotinib", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "conventional surgery", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Nathan Pennell, MD, PhD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2005-10", "completion_date": "2011-02", "has_results": true, "last_update_posted_date": "2020-07-20", "last_synced_at": "2026-10-19T08:43:57.561Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00278148" }, { "nct_id": "NCT06011772", "title": "EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Colo-rectal Cancer" ], "interventions": [ { "name": "Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine", "type": "BIOLOGICAL" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Cetuximab", "type": "BIOLOGICAL" }, { "name": "Metastasectomy", "type": "PROCEDURE" }, { "name": "Biospecimen collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Panitumumbab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2023-12-18", "completion_date": "2029-02-05", "has_results": false, "last_update_posted_date": "2026-08-21", "last_synced_at": "2026-10-19T08:43:57.561Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06011772" }, { "nct_id": "NCT01063075", "title": "A Study in Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Solid Tumor" ], "interventions": [ { "name": "Cetuximab", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "5 - FU", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 34, "start_date": "2010-06", "completion_date": "2015-10", "has_results": true, "last_update_posted_date": "2019-09-26", "last_synced_at": "2026-10-19T08:43:57.561Z", "location_count": 6, "location_summary": "Fayetteville, Arkansas • Fairway, Kansas • Portland, Oregon + 2 more", "locations": [ { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Fairway", "state": "Kansas" }, { "city": "Portland", "state": "Oregon" }, { "city": "Portland", "state": "Oregon" }, { "city": "Charleston", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01063075" }, { "nct_id": "NCT07322094", "title": "CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ovarian Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "FIGO Stage III and IV Ovarian Cancer", "Fallopian Tube Cancers", "Primary Peritoneal Cancer" ], "interventions": [ { "name": "TORL-1-23 and paclitaxel", "type": "COMBINATION_PRODUCT" }, { "name": "TORL-1-23 and carboplatin", "type": "COMBINATION_PRODUCT" }, { "name": "TORL-1-23, paclitaxel, and carboplatin", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "COMBINATION_PRODUCT" ], "sponsor": "TORL Biotherapeutics, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "FEMALE", "summary": "18 Years to 75 Years · Female only" }, "enrollment_count": 60, "start_date": "2025-12-10", "completion_date": "2028-01", "has_results": false, "last_update_posted_date": "2026-07-13", "last_synced_at": "2026-10-19T08:43:57.561Z", "location_count": 7, "location_summary": "Fullerton, California • Irvine, California • Los Angeles, California + 3 more", "locations": [ { "city": "Fullerton", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT07322094" }, { "nct_id": "NCT07059845", "title": "A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ovarian Cancer" ], "interventions": [ { "name": "Mirvetuximab Soravtansine", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 400, "start_date": "2025-11-13", "completion_date": "2029-01", "has_results": false, "last_update_posted_date": "2026-10-13", "last_synced_at": "2026-10-19T08:43:57.561Z", "location_count": 31, "location_summary": "La Jolla, California • Solvang, California • Gainesville, Florida + 28 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Solvang", "state": "California" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "St. Petersburg", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07059845" }, { "nct_id": "NCT05059327", "title": "Basimglurant (NOE-101) in Children, Adolescents, and Young Adults With TSC", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Tuberous Sclerosis Complex" ], "interventions": [ { "name": "Basimglurant with crossover to Placebo", "type": "DRUG" }, { "name": "Placebo with crossover to Basimglurant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Noema Pharma AG", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "5 Years", "maximum_age": "30 Years", "sex": "ALL", "summary": "5 Years to 30 Years" }, "enrollment_count": 61, "start_date": "2022-03-03", "completion_date": "2025-04-28", "has_results": false, "last_update_posted_date": "2025-06-04", "last_synced_at": "2026-10-19T08:43:57.561Z", "location_count": 9, "location_summary": "Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts + 6 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Royal Oak", "state": "Michigan" }, { "city": "Roseville", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT05059327" }, { "nct_id": "NCT02446886", "title": "Adrenocorticotropic Hormone (ACTH) Effects on Myelination in Subjects With MS", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Multiple Sclerosis" ], "interventions": [ { "name": "Adrenocorticotropic hormone (ACTH) gel (H.P. Acthar®)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Weill Medical College of Cornell University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2016-06", "completion_date": "2020-06", "has_results": true, "last_update_posted_date": "2021-01-22", "last_synced_at": "2026-10-19T08:43:57.561Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02446886" }, { "nct_id": "NCT03814590", "title": "A Study to Assess the Safety, Reactogenicity and Immune Response of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3844766A) in Older Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Respiratory Syncytial Virus Infections" ], "interventions": [ { "name": "RSV Vaccine (GSK3844766A) unadjuvanted low dose", "type": "BIOLOGICAL" }, { "name": "RSV Vaccine (GSK3844766A) low dose adjuvanted with AS01E", "type": "BIOLOGICAL" }, { "name": "RSV Vaccine (GSK3844766A) low dose adjuvanted with AS01B", "type": "BIOLOGICAL" }, { "name": "RSV Vaccine (GSK3844766A) unadjuvanted medium dose", "type": "BIOLOGICAL" }, { "name": "RSV Vaccine (GSK3844766A) medium dose adjuvanted with AS01E", "type": "BIOLOGICAL" }, { "name": "RSV Vaccine (GSK3844766A) medium dose adjuvanted with AS01B", "type": "BIOLOGICAL" }, { "name": "RSV Vaccine (GSK3844766A) unadjuvanted high dose", "type": "BIOLOGICAL" }, { "name": "RSV Vaccine (GSK3844766A) high dose adjuvanted with AS01E", "type": "BIOLOGICAL" }, { "name": "RSV Vaccine (GSK3844766A) high dose adjuvanted with AS01B", "type": "BIOLOGICAL" }, { "name": "Placebo (Saline solution)", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 1053, "start_date": "2019-01-21", "completion_date": "2020-11-30", "has_results": true, "last_update_posted_date": "2022-08-05", "last_synced_at": "2026-10-19T08:43:57.561Z", "location_count": 18, "location_summary": "Jacksonville, Florida • Miami, Florida • Stockbridge, Georgia + 15 more", "locations": [ { "city": "Jacksonville", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Stockbridge", "state": "Georgia" }, { "city": "Lenexa", "state": "Kansas" }, { "city": "Wichita", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03814590" }, { "nct_id": "NCT06996782", "title": "A Platform Study in Non-Small Cell Lung Cancer (NSCLC)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced or Metastatic Non-small Cell Lung Cancer" ], "interventions": [ { "name": "Rilvegostomig", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Ramucirumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 152, "start_date": "2025-11-24", "completion_date": "2029-02-23", "has_results": false, "last_update_posted_date": "2026-10-01", "last_synced_at": "2026-10-19T08:43:57.561Z", "location_count": 10, "location_summary": "Phoenix, Arizona • Santa Rosa, California • Jacksonville, Florida + 6 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Santa Rosa", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT06996782" } ] }